Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases.
10.19540/j.cnki.cjcmm.20170705.011
- Author:
Xing LIAO
1
;
Dan-Dan YU
1
;
Yan-Ming XIE
1
;
Yun-Ling ZHANG
2
;
Yan HE
3
;
Yin ZHANG
1
;
Yan LIU
4
;
Dan-Hui YI
4
;
Yong-Yan WANG
1
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
2. Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China.
3. Affiliated Hospital of Chengdu University of Taditional Chinese Medicine, Chengdu 610072, China.
4. School of Statistics, Renmin University of China, Beijing 100872, China.
- Publication Type:Journal Article
- Keywords:
ADR;
Diemailing Kudiezi injection;
hospital based intensive monitoring;
post-marketing safety surveillance;
real world
- From:
China Journal of Chinese Materia Medica
2017;42(15):2857-2863
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to obtain the incidence of adverse drug reaction (ADR) of Diemailing Kudiezi injection, explore its characteristics, related risk factors and application in real world. A prospective single cohort study was conducted from 25 hospitals (including Chinese medicine hospitals and Western medicine hospitals) for 4 years. 30 233 consecutive inpatients using Diemailing Kudiezi injection were observed. Their general information was analyzed by using statistic frequency description. Association rules were used to analyze the correlation between comorbidities or drug combinations; the influential factors for ADRs were initially screened by using cross contingency method and Chi-square test, and then Group LASSAO method was used for further analysis. 54 patients with adverse drug events and 30 patients with ADRs were reported among 30 233 patients, with a total ADR incidence of 0.099%[95%CI (0.06%, 0.13%)]. There were 27 patients identified as the "general" ADR, one patients with "severe" ADR (anaphylactic shock) and two patients with new ADRs. ADR occurred most in 30 min after using Diemailing Kudiezi injection, in a total of 16 patients. The most ADRs were palpitation, vomiting, chills, pruritus and rash, 6 times for each symptom. Diemailing Kudiezi injection was well tolerated in the general population. The overall incidence of adverse reactions was rare, with high safety. However, the real incidence of ADRs may be underestimated in this study, and the blood samples were not obtained for the patients, so further mechanism studies shall be conducted.
